Coastline Trust Co Boosts Stake in Eli Lilly and Company

Got story updates? Submit your updates here. ›

Coastline Trust Co, an investment management firm, increased its stake in Eli Lilly and Company by 12% in the fourth quarter of 2025, according to a recent SEC filing. The firm now owns 20,225 shares of the pharmaceutical company's stock, valued at $21.74 million, making it one of Eli Lilly's larger institutional investors.

Why it matters

Eli Lilly is a major player in the pharmaceutical industry, with a diverse portfolio of drugs and a robust pipeline of new treatments. The increase in Coastline Trust Co's stake suggests the firm sees long-term growth potential in Eli Lilly's business, which could signal broader investor confidence in the company's future performance.

The details

Coastline Trust Co purchased an additional 2,166 shares of Eli Lilly in Q4 2025, bringing its total holding to 20,225 shares. This represents approximately 2% of the firm's total investment portfolio. Eli Lilly and Company is now Coastline Trust Co's 12th largest position.

• Coastline Trust Co increased its stake in Eli Lilly during the fourth quarter of 2025.
• Coastline Trust Co's holdings in Eli Lilly were valued at $21.74 million as of the most recent SEC filing.